• 原料直供
• 试剂商城
• 直接询价

分类

• {SNA} Antibacterial, Antibiotics, Antibiotics A to Z, Antibiotics N-S, Antimycobacterial, Biochemicals and Reagents, L - Z, Spectrum of Activity
• {SNA} Antibacterial, Antibiotics, Antibiotics A to Z, Antibiotics N-S, Antimycobacterial, L - Z, Spectrum of Activity
• Heterocycles
• Amide
• Pharmaceuticals
• {SNA} Antibacterial, Antibiotics A to Z, Antibiotics N-S, Antimycobacterial, L - Z, Spectrum of Activity, 抗生素, 生化试剂
• {uni_hamburg} no charge; nitrogen heterocycle; aromatic; 6RingOnly; 6ring; amide; 1fragment
• Intermediates & Fine Chemicals,

产品应用

• An antibacterial agent used to study liver toxicity prevention.

相关文献及参考

• Weiner, I.M., et al.: J. Pharmacol. Exp. Ther., 180, 411 (1972),
• Short: III/10a Title: Structure Data of Organic Crystals: C ... C 15 Author: Schudt-Weitz, G.; Strell, I. Editor: Hellwege, K.-H.; Hellwege, A.M. Source: Landolt-Börnstein, New Series Volume: III/10a Year: 1985 ISBN: 3-540-07834-7 ISBN: 978-3-540-07834-0 Internet Resource: DOI:10.1007/b19984 RefComment: XXII, 634 pages. Hardcover Abstract: The volume includes an alphabetical index of all substances and a separate "ring index" with all cyclic compounds.
• Short: III/5a Title: Structure Data of Organic Crystals: C ... C 13 Author: Schudt, E.; Weitz, G. Editor: Hellwege, K.-H.; Hellwege, A.M. Source: Landolt-Börnstein, New Series Volume: III/5a Year: 1971 ISBN: 3-540-05177-5 ISBN: 978-3-540-05177-0 Internet Resource: DOI:10.1007/b19970 RefComment: XXI, 736 pages, and VII, 890 pages. Hardcover Abstract: Volume III/5 offers a compitation as complete as possible of the space groups and lattice con-stants of all crystals which have been studied by means of X-rays, neutron and electron diffraction.
• Short: IV/20B Title: Vapor Pressure and Antoine Coefficients for Oxygen Containing Organic Compounds Author: Dykyj, J.; Svoboda, J.; Wilhoit, R.C.; Frenkel, M.; Hall, K.R. Editor: Hall, K.R. Source: Landolt-Börnstein, New Series Volume: IV/20B Year: 2000 Keyword: organic compounds; vapor pressure ISBN: 3-540-64968-9 ISBN: 978-3-540-64968-7 Internet Resource: DOI:10.1007/b71424 RefComment: VII, 320 pages.
• Short: IV/20C Title: Vapor Pressure and Antoine Coefficients for Nitrogen Containing Organic Compounds Author: Dykyj, J.; Svoboda, J.; Wilhoit, R.C.; Frenkel, M.; Hall, K.R. Editor: Hall, K.R. Source: Landolt-Börnstein, New Series Volume: IV/20C Year: 2001 Keyword: organic compounds; vapor pressure ISBN: 3-540-41060-0 ISBN: 978-3-540-41060-7 Internet Resource: DOI:10.1007/b88812 RefComment: VII, 197 pages
• Short: IV/8A Title: E

安全信息

GHS Symbol

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 328 gm/kg/78W-C
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Blood - lymphoma, including Hodgkin's disease
REFERENCE :
   NCITR* National Cancer Institute Carcinogenesis Technical Report Series.
   (Bethesda, MD)  No.0-205. For publisher information, see NTPTR*.
   Volume(issue)/page/year: NCI-TR-48,1978

TYPE OF TEST            : TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 756 gm/kg/30W-C
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Lungs, Thorax, or Respiration - tumors
REFERENCE :
   GANNA2 Gann.  Japanese Journal of Cancer Research.  (Tokyo, Japan)  V.1-75,
   1907-84.  For publisher information, see JJCREP.  Volume(issue)/page/year:
   51,83,1960

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 2973 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   NIIRDN Drugs in Japan (Ethical Drugs).  (Yakugyo Jiho Co., Ltd., Tokyo,
   Japan)  Volume(issue)/page/year: -,1038,1995

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 3 gm/kg
TOXIC EFFECTS :
   Behavioral - excitement
   Behavioral - ataxia
REFERENCE :
   ARTUA4 American Review of Tuberculosis.  (New York, NY)  V.1-70, 1917-54.
   For publisher information, see ARDSBL.  Volume(issue)/page/year: 70,423,1954

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 3 gm/kg
TOXIC EFFECTS :
   Behavioral - excitement
   Behavioral - ataxia
REFERENCE :
   ARTUA4 American Review of Tuberculosis.  (New York, NY)  V.1-70, 1917-54.
   For publisher information, see ARDSBL.  Volume(issue)/page/year: 70,423,1954

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 10 mg/kg
TOXIC EFFECTS :
   Vascular - BP elevation not characterized in autonomic section
REFERENCE :
   JAMAAP JAMA, Journal of the American Medical Association.  (AMA, 535 N.
   Dearborn St., Chicago, IL 60610)  V.1-    1883-  Volume(issue)/page/year:
   127,1356,1997

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 1680 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal

TYPE OF TEST            : Sperm Morphology
ROUTE OF EXPOSURE       : Intraperitoneal
TEST SYSTEM             : Rodent - mouse
DOSE/DURATION           : 500 mg/kg
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 321,1,1994

TYPE OF TEST            : Mutation test systems - not otherwise specified
ROUTE OF EXPOSURE       : Intraperitoneal
TEST SYSTEM             : Rodent - mouse
DOSE/DURATION           : 500 mg/kg
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 321,1,1994

TYPE OF TEST            : Cytogenetic analysis
ROUTE OF EXPOSURE       : Intraperitoneal
TEST SYSTEM             : Rodent - mouse
DOSE/DURATION           : 250 mg/kg
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 321,1,1994

TYPE OF TEST            : Cytogenetic analysis
TEST SYSTEM             : Human Lymphocyte
DOSE/DURATION           : 300 mg/L
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 48,215,1977

其他信息

• Acros Organics:吡嗪酰胺 Pyrazinamide, 99%(98-96-4)
• MOL 文件:98-96-4.mol
• 抗结核药物:吡嗪酰胺 是一种第二线抗结核药物，又称为吡嗪甲酰胺、氨甲酰基吡嗪、异烟酸胺，常温下为白色结晶性粉末，微溶于水，无臭，味微苦。对人型结核杆菌有较好 的抗菌作用，pH值介于5-5.5之间时，杀菌作用最强，尤其对处于酸性环境中缓慢生长的吞噬细胞内的结核菌效果最佳。吡嗪酰胺渗透入吞噬细胞后并进入结核杆菌 菌体内，菌体内的酰胺酶使其脱去酰胺基，转化为吡嗪酸而发挥抗菌作用。 在体内抑菌浓度12.5μg/ml，达50μg/ml可杀灭结核杆菌。在细胞内抑制结核杆菌的浓度比在细胞外低10倍，在中性、碱性环境中几乎无抑菌作用。 抑菌作用介于链霉素与对氨基水杨酸钠之间，毒性大，易产生耐药性,需与其它抗结核药物联合应用。 吡嗪酰胺在化学结构上与烟酰胺相似，通过取代烟酰胺而干扰脱氢酶，阻止脱氢作用，抑制结核杆菌对氧的利用，导致细菌不能正常代谢而死亡。 口服易吸收，广泛分布于全身组织和体液中，包括肝、肺、脑脊液，肾及胆汁。2小时后达血药高峰。脑脊液与血浓度相近、肝代谢，水解成呲嗪酸，为具有抗菌活 性的代谢物，继而羟化成为无活性的代谢物，经肾小球滤过后尿排泄。t1/2为8～10小时。可与其他抗结核药配合，用于一些复杂肺结核病例及结核性脑膜炎患者。
• TCI Shanghai:吡嗪酰胺 Pyrazinamide,>;98.0%(T)(98-96-4)
• Sigma Aldrich:98-96-4(sigmaaldrich)
• Pyrazinamide
• 海关编码:
• 图谱信息:吡嗪酰胺(98-96-4)红外图谱(IR2) 吡嗪酰胺(98-96-4)核磁图( 1 HNMR) 吡嗪酰胺(98-96-4)质谱(MS) 吡嗪酰胺(98-96-4)核磁图( 13 CNMR) 吡嗪酰胺(98-96-4)红外图谱(IR1)
• 不良反应与副作用:长期或大剂量使用该品易引起肝脏损害、血尿酸增高，还可引起胃肠道刺激及过敏反应。 发生率较高者：食欲减退、发热、异常乏力或软弱、眼或皮肤黄染(肝毒性)。 发生率较少者：畏寒、关节肿痛(尤其大趾、髁、膝关节)或病变关节皮肤拉紧发热(急性痛风性关节痛)。 应用本品疗程中血尿酸常增高，可引起急性痛风发作，须进行血清尿酸测定。 不良反应与剂量疗程有关，目前应用常规剂量后，不良反应已少见。 肝损害：每日服药3g时，约15％患者出现肝损害、肝肿大、压痛、转氨酶升高、黄疸等。目前采用每日1.5g，疗程3个月，肝毒性反应并不多见。 关节痛：PZA的代谢产物可抑制尿酸的排泄，引致高尿酸血症和痛风样表现，停药后可恢复。 胃肠道反应：食欲不振、恶心、呕吐。 过敏反应：偶见发热及皮疹，甚至可出现黄疸。 皮肤反应：个别对光敏感，皮肤暴光部位呈鲜红棕色。长期服药者，皮肤呈古
• 吡嗪酰胺价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2014/06/02 P0633 吡嗪酰胺 Pyrazinamide
• 急救处理:1.误服者立即予以洗胃、导泻。 2.治疗过程中出现肝功能损害者应停药，并给予护肝治疗。 3.有痛风发作者给予丙磺舒（羧苯磺胺）0.25g／次，每日3次口服，可促进尿酸的排泄。 4.有过敏者
• 吡嗪酰胺价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2014/06/02 P0633 吡嗪酰胺 Pyrazinamide 25G 531元 2010/06/21 157640250 吡嗪酰胺 Pyrazinamide 99% 25 GR 621元 2010/06/21 157641000 吡嗪酰胺 Pyrazinamide 99% 1
• Pyrazinamide 是一种治疗肺结核的药物。
• 用法用量:与其他抗结核药联合治疗，成人口服常用量为：每6小时按体重5-8.75mg/kg,或每8小时按体重6.7-11.7mg/kg，最高每日3g。 治疗异烟肼耐药菌感染时可增加至每日60mg/kg。 儿童慎用，必须使用的参考用量为：每日20-25mg/kg，分3次口服，最高每日2g，疗程一般2～3个月，不得超过6个月。